


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-9.31%
+4.40%
-0.68%
+1.29%
TXG
10x Genomics
$16.53
Strengths

Earnings are forecast to grow

Investors confidence is positive
Chart
$11.6 (+42.50%)
$13.36 (+23.73%)
$10.87 (+52.07%)
$13.29 (+24.38%)
TXG has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

TXG overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
TXG Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TXG Street Sentiment is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is TXG current stock price?
What are TXG stock strengths?
What risks are associated with TXG stock?
When is TXG next earnings report?
What is TXG market cap and volume?
What is TXG's current Stock IQ?
Should I buy TXG stock right now?
Is TXG a Strong Buy right now?
What does a 'Strong Buy' rating mean for TXG?
What does a 'Strong Sell' rating mean for TXG?
What factors influence TXG's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-9.31%
+4.40%
-0.68%
+1.29%
TXG
10x Genomics
Current Price
$16.53
Stock Insights
Strengths

Earnings are forecast to grow

Investors confidence is positive

Chart
$11.6 (+42.50%)
$13.36 (+23.73%)
$10.87 (+52.07%)
$13.29 (+24.38%)
TXG Analysts Opinion
TXG Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
TXG Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TXG Street Sentiment is extremely bullish and have negative views on the near-term outlook
TXG has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels.
TXG Latest Analysis
10x Genomics (TXG) Soars to New Record High on Lower Net Loss Revenue Beat. We recently published 10 Stocks Beating the Market with Eye-Popping Gains. 10x Genomics Inc. (NASDAQ:TXG) is one of the best-performing stocks on Monday. Shares of 10x Genomics propelled to a new 52-week high after narrowing its net loss and beating its revenue guidance for the third quarter of the year. At intra-day trading the stock [….]
Tue Nov 11, 2025
TXG Crosses Above Average Analyst Target. In recent trading shares of 10x Genomics Inc (Symbol: TXG) have crossed above the average analyst 12-month target price of $14.86 changing hands for $15.25/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade on valu
Mon Nov 10, 2025
10x Genomics (TXG) Reports Q3 Loss Beats Revenue Estimates. 10x Genomics (TXG) delivered earnings and revenue surprises of 18.52% and 4.64% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Thu Nov 6, 2025
10x Genomics GAAP EPS of -$0.22 beats by $0.08 revenue of $149M beats by $6.48M.
Thu Nov 6, 2025
Lancaster Opens $7 Million Position in 10x Genomics (TXG). Key PointsLancaster Investment Management bought over 620000 shares in 10x Genomics (TXG) worth around $7.27 million.
Fri Oct 24, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.